MX2021014634A - Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas. - Google Patents

Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas.

Info

Publication number
MX2021014634A
MX2021014634A MX2021014634A MX2021014634A MX2021014634A MX 2021014634 A MX2021014634 A MX 2021014634A MX 2021014634 A MX2021014634 A MX 2021014634A MX 2021014634 A MX2021014634 A MX 2021014634A MX 2021014634 A MX2021014634 A MX 2021014634A
Authority
MX
Mexico
Prior art keywords
lysozyme
methods
same
pharmaceutical formulations
broad spectrum
Prior art date
Application number
MX2021014634A
Other languages
English (en)
Spanish (es)
Inventor
Diogenes Aybar-Batista
Original Assignee
Aybar Ecotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aybar Ecotechnologies Corp filed Critical Aybar Ecotechnologies Corp
Publication of MX2021014634A publication Critical patent/MX2021014634A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021014634A 2019-05-28 2020-05-28 Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas. MX2021014634A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853215P 2019-05-28 2019-05-28
PCT/IB2020/055083 WO2020240472A1 (en) 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same

Publications (1)

Publication Number Publication Date
MX2021014634A true MX2021014634A (es) 2022-07-04

Family

ID=73551002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014634A MX2021014634A (es) 2019-05-28 2020-05-28 Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas.

Country Status (12)

Country Link
US (3) US20200376094A1 (cg-RX-API-DMAC10.html)
EP (1) EP3976093A4 (cg-RX-API-DMAC10.html)
JP (3) JP7768769B2 (cg-RX-API-DMAC10.html)
CN (1) CN114126643A (cg-RX-API-DMAC10.html)
AR (1) AR119031A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021024001A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145530A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021017958A2 (cg-RX-API-DMAC10.html)
IL (1) IL288531A (cg-RX-API-DMAC10.html)
MX (1) MX2021014634A (cg-RX-API-DMAC10.html)
TW (1) TW202110474A (cg-RX-API-DMAC10.html)
WO (1) WO2020240472A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
WO2023133412A2 (en) * 2022-01-05 2023-07-13 Prophase Labs, Inc. Compositions having synergistic anti-viral action and methods for treating coronavirus
CN114503981A (zh) * 2022-01-07 2022-05-17 上海膜益信息科技有限公司 一种不分层防霉液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
CN1557485A (zh) * 2004-01-30 2004-12-29 大连帝恩生物工程有限公司 基因重组人溶菌酶在消除病原微生物感染炎症上的应用
ES2369670T3 (es) * 2004-04-08 2011-12-02 Dermcare-Vet Pty Ltd Composiciones antimicrobianas y métodos para su uso.
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
EP2207893B1 (en) * 2007-10-19 2011-12-28 Becton, Dickinson and Company Methods for the detection of beta-lactamases
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
UA48016U (ru) * 2010-01-25 2010-02-25 Илона Васильевна Ковач Способ профилактики кариеса зубов у детей 3-6 лет
UA68612U (ru) * 2012-02-07 2012-03-26 Дмитрий Викторович Дудар Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией
CN105611909B (zh) * 2013-03-12 2020-09-15 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
WO2019018368A1 (en) * 2017-07-17 2019-01-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ANTIBACTERIAL METHODS AND ASSOCIATED KITS
CN107899006A (zh) * 2017-11-28 2018-04-13 四川清舒乐科技有限公司 冲洗鼻腔的药物组合物及其制备方法

Also Published As

Publication number Publication date
US20240066105A1 (en) 2024-02-29
EP3976093A1 (en) 2022-04-06
AR119031A1 (es) 2021-11-17
CA3145530A1 (en) 2020-12-03
BR112021024001A2 (pt) 2022-01-25
CO2021017958A2 (es) 2022-01-17
US20220362354A1 (en) 2022-11-17
IL288531A (en) 2022-01-01
JP2022534776A (ja) 2022-08-03
JP2025038034A (ja) 2025-03-18
WO2020240472A1 (en) 2020-12-03
EP3976093A4 (en) 2023-07-05
CN114126643A (zh) 2022-03-01
JP2026021451A (ja) 2026-02-10
JP7768769B2 (ja) 2025-11-12
US20200376094A1 (en) 2020-12-03
TW202110474A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
SA520411204B1 (ar) مترافقات سيتوكين لعلاج الأمراض التكاثرية والمعدية
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2019014041A (es) Inhibidores pirazolicos de magl.
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
CY1125882T1 (el) Αναστολεις της magl πυραζολιου
EP4241769A3 (en) Bisphosphocin gel formulations and uses thereof
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
UY37665A (es) Formas cristalinas de (s)-afoxolaner
AU2017248276A1 (en) Methods of treating ocular conditions
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
EP3897593A4 (en) CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
EP3919498A4 (en) PYRAZOLOPYRIMIDI DERIVATIVE AND USE THEREOF
EP3897615A4 (en) CANNABIS COMPOSITIONS AND METHODS
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
MX394833B (es) Formulaciones con mejora de la estabilidad.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
IL288531A (en) Broad-spectrum antibacterial pharmaceutical formulations comprising lyses and methods of using them
EP3893833C0 (fr) Gelée de parfum
IL287729A (en) Antibiotic cannabinoid-terpene formulations